Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 50% Improvement Relative Risk c19hcq.org Lora-Tamayo et al. HCQ for COVID-19 LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? Retrospective 8,553 patients in Spain Lower mortality with HCQ (p<0.000001) Lora-Tamayo et al., J. Infection, doi:10.1016/j.jinf.2021.02.011 Favors HCQ Favors control
Early Lopinavir/ritonavir does not reduce mortality in COVID-19 patients: results of a large multicenter study
Lora-Tamayo et al., J. Infection, doi:10.1016/j.jinf.2021.02.011
Lora-Tamayo et al., Early Lopinavir/ritonavir does not reduce mortality in COVID-19 patients: results of a large multicenter study, J. Infection, doi:10.1016/j.jinf.2021.02.011
Feb 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Lopinavir/ritonavir retrospective study also showing univariate results for HCQ, with significantly lower mortality.
risk of death, 50.5% lower, RR 0.50, p < 0.001, treatment 7,192, control 1,361, odds ratio converted to relative risk, univariate, control prevalence approximated with overall prevalence.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Lora-Tamayo et al., 11 Feb 2021, retrospective, Spain, peer-reviewed, 10 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: Journal of Infection 82 (2021) 276–316 Contents lists available at ScienceDirect Journal of Infection journal homepage: www.elsevier.com/locate/jinf Letters to the Editor Short durations of corticosteroids for hospitalised COVID-19 patients are associated with a high readmission rate Dear Editor,
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit